These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29995658)

  • 1. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
    Aguilar C
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
    Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
    J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
    Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
    Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
    Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
    Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
    [No Abstract]   [Full Text] [Related]  

  • 9. Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
    Busygina K; Denzinger V; Bernlochner I; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Aug; 119(8):1212-1221. PubMed ID: 31087308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Major Bleeding with Ibrutinib.
    Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
    Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
    Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
    Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
    Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
    Liu L; Shi B; Wang X; Xiang H
    Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.